Clinical Pharmacokinetic Studies of Enzalutamide
Conclusions Enzalutamide has predictable pharmacokinetics, with low intersubject variability. Similar efficacy was observed in patients across the concentration/exposure range associated with a fixed oral dose of enzalutamide 160 mg/day.
ConclusionsAfter treatment with AA or ENZ, elderly prostate cancer patients with pre-existing CVDs experienced higher short-term mortality than otherwise similar patients without CVDs. Mortality associated with CVDs did not depend on having received AA versus ENZ.Patient summaryPatients with pre-existing cardiovascular diseases (CVDs) experienced higher short-term mortality after abiraterone acetate or enzalutamide than those without pre-existing CVDs. It is recommended that a multidisciplinary team, including a cardiologist, evaluate patients having pre-existing CVDs in the process of making treatment decisions and monito...
AbstractThe aim of our study is to investigate the efficacy of metronomic cyclophosphamide plus low dose of corticosteroids in advanced or metastatic castration-resistant prostate cancer (CRPC) before, between, and after standard chemotherapy, such as docetaxel and cabazitaxel, and new hormonal treatments, such as abiraterone and enzalutamide. A retrospective analysis was performed on 37 patients. Cyclophosphamide was given orally 50 mg per day together with low dose of corticosteroids, namely dexametasone orally 1 mg per day or prednisone 10 mg per day. Seventeen patients (51%) showed a PSA decline≥&thi...
ConclusionsOverall risk of cancer in our MS cohort did not significantly differ from the controls. However, the age at diagnosis of breast cancer was statistically significantly higher among the MS patients in comparison with a control population from the same patient pool. Further population-based larger studies spanning longer follow-up periods and longer exposure to emerging MS therapies are needed to evaluate cancer risk related to MS treatments and breast cancer risk in particular.
Objective: To evaluate the occurrence of nonsyndromic cleft lip and/or palate (NSCL/P) in families of patients with prostate cancer (PC).Study design: We conducted a case-control study involving a total of 748 individuals, 280 of which had PC, and 468 were free-cancer healthy individuals. The patients answered a questionnaire with basic demographic information and family history of NSCL/P in first-degree relatives. The information collected was stored in a database and analyzed by using the statistical program SPSS® 24.0for Windows (Chicago, IL, USA). In order to determine the association with NSCL/P, chi-square and Fi...
Prostate-specific membrane antigen (PSMA)-targeted PET tracers have improved early detection of oligometastatic (OM) prostate cancer. Evidence suggests that stereotactic ablative radiotherapy (SABR) for OM prostate cancer may improve clinical outcomes, but localization of multiple small lesions for treatment is challenging with conventional X-ray-based imaging systems, limiting deliverable doses. Biologically-guided radiotherapy (BgRT) is being developed to utilize strong contrast of PET signal for real-time intra-fraction tracking of multiple targets.
Conclusion: The safety profile of cabazitaxel in this pooled analysis of two cabazitaxel early access programmes was manageable and consistent with previous Phase III trials (TROPIC, PROSELICA). PMID: 31289614 [PubMed]
Conclusion: This study showed that periodontal diseases were associated with increased risk of several cancers. Besides other wellknown benefits for health, the provision of oral/dental health should be considered and employed as a cancer prevention measure. PMID: 31195790 [PubMed - as supplied by publisher]
Neuroendocrine prostate cancer (NEPC) is a lethal prostate malignancy with a median survival of less than 1 year from time of detection. NEPC can occur de novo or more commonly as a treatment emergent phenomenon (t-NEPC). t-NEPC occurs in a subset of patients with metastatic-castration resistant prostate cancer. Two cases of t-NEPC with oral manifestations are presented highlighting the pathologic features and the varied clinical context in which these lesions presented.
Secreted proteins are involved in several physiological mechanisms. In solid tumors, it can be used as diagnostic and prognostic tools. Human anterior gradient 2 (AGR2) and CD10 are proteins secreted in body fluids in prostate cancer. The main of this study was to evaluate expression of the secreted proteins AGR2 and CD10 in adenoid cystic carcinoma (ACC) of the salivary gland. A total of 20 cases of ACC of the salivary glands were examined by immunohisto-chemistry method. Female was more affected (70%) with age varying from 10 to 79.
The objective of this brief article is to discuss the typical patient profile for use of apalutamide and to review the pros and cons of use and common side effects and management. PMID: 31180310 [PubMed - in process]